EP Patent

EP3184095A1 — Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide

Assigned to IP Gesellschaft fuer Management mbH · Expires 2017-06-28 · 9y expired

What this patent protects

The invention relates to a packaging comprising one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid.

USPTO Abstract

The invention relates to a packaging comprising one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid.

Drugs covered by this patent

Patent Metadata

Patent number
EP3184095A1
Jurisdiction
EP
Classification
—
Expires
2017-06-28
Drug substance claim
No
Drug product claim
No
Assignee
IP Gesellschaft fuer Management mbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.